Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Krystal Biotech, Inc.    KRYS

KRYSTAL BIOTECH, INC.

(KRYS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
KRYSTAL BIOTECH, INC.-4.30%1 042
-
GILEAD SCIENCES12.87%91 996
VERTEX PHARMACEUTICALS30.15%73 883
REGENERON PHARMACEUTICALS51.78%63 465
WUXI APPTEC CO., LTD.14.69%24 438
GENMAB A/S36.89%19 339
BEIGENE, LTD.-4.01%12 339
SAREPTA THERAPEUTICS, INC.16.71%11 745
NEUROCRINE BIOSCIENCES, INC..16.10%11 590
BIONTECH SE50.62%11 573
HUALAN BIOLOGICAL ENGINEERI..52.23%10 533
EXELIXIS, INC.39.73%7 550
ASCENDIS PHARMA A/S5.34%7 032
ARGENX SE1.18%6 773
MYOKARDIA, INC.47.49%5 583
-
BIOCON LIMITED19.27%5 452
More Results
Financials (USD)
Sales 2020 -
EBIT 2020 -38,8 M
Net income 2020 -38,1 M
Finance 2020 261 M
Yield 2020 -
P/E ratio 2020 -25,8x
P/E ratio 2021 -20,5x
EV / Sales2020 infx
EV / Sales2021 72,0x
Capitalization 1 042 M
Upcoming event on KRYSTAL BIOTECH, INC.
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating -
Growth (Revenue) -
Valuation -
Finances -
Profitability -
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes